

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operat or	Plural s	Time Stamp
L1	717	514/57	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 09:52
L2	589	I1 and composition	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:04
L3	518	I2 and (dextran or starch or cellulose)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:04
L4	307	I3 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:04
L5	74	I4 and encapsul\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:05
L6	41	I5 and emuls\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:05

## EAST Search History

L7	524	514/59	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:04
L8	431	I7 and composition	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:07
L9	372	I8 and (dextran or starch or cellulose)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:08
L10	298	I9 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:29
L11	69	I10 and encapsul\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:29
L12	29	I11 and emuls\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:29

## EAST Search History

L13	189	536/45	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:07
L14	112	I13 and composition	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:31
L15	104	I14 and (dextran or starch or cellulose)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:33
L16	52	I15 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:34
L17	8	I16 and encapsul\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:34
L18	6	I17 and emuls\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:40

## EAST Search History

L19	663	536/1.11	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:31
L20	444	I19 and composition	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:36
L21	277	I20 and (dextran or starch or cellulose)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:37
L22	212	I21 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:35
L23	57	I22 and encapsul\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:36
L24	585	536/55.1	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:35

## EAST Search History

L25	405	I24 and composition	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:35
L26	330	I25 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:35
L27	48	I26 and encapsul\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:39
L28	3067	424/490	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:36
L29	2611	I28 and composition	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:37
L30	2088	I29 and (polysaccharide or dextran or starch or cellulose)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:37

## EAST Search History

L31	1101	I30 and encapsul\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:39
L32	734	I31 and emuls\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:41
L33	521	I32 and (PEG or PEO or polyvinyl)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:42
L34	458	I33 and particles	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:47
L35	3	I34 and (oil ADJ in ADJ water)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2007/07/20 10:44

dis hist

(FILE 'HOME' ENTERED AT 11:18:20 ON 20 JUL 2007)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, EMBASE, MEDLINE, BIOSIS' ENTERED AT 11:20:12 ON 20 JUL 2007

L1 7433789 S COMPOSITION  
L2 554816 S L1 AND (POLYSACCHARIDE OR DEXTRAN OR STARCH OR CELLULOSE)  
L3 8 S L2 AND ECAPSUL?  
L4 69931 S L2 AND ENCAPSUL?  
L5 55983 S L4 AND (EPO OR ERYTHROPOIETIN OR CSF OR TPA OR INTERFERON O  
L6 20251 S L5 AND (PEG OR PEO OR PVP OR PVA)  
L7 0 S L6 AND (SOLID(A) OIL(A) WATER(A) EMULSION)  
L8 20192 S L6 AND (METHOD OR PROCESS)  
L9 16 S L8 AND (PARTICLES(W) DIAMETER)  
L10 7614 S L6 AND MICROSPHERE  
L11 1444 S L10 AND CHITOSAN  
L12 1338 S L11 AND DRUG  
L13 405 S L12 AND (PREDNISOLONE OR CORTISONE)  
L14 236 S L13 AND (CELLULOSE(A) ACETATE)  
L15 181 S L14 AND (SUSTAINED(A) RELEASE)  
L16 83 S L15 AND (AQUEOUS(W) SUSPENSION)

FILE 'CAPLUS' ENTERED AT 11:52:04 ON 20 JUL 2007

L17 36 S JIN TUO/AU  
L18 2 S L17 AND ENCAPSUL?  
L19 198 S ZHU HUA/AU  
L20 1 S L19 AND ENCAPSUL?  
L21 4 S ZHU JIAHAO/AU

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 3 MAR 16 CASREACT coverage extended  
NEWS 4 MAR 20 MARPAT now updated daily  
NEWS 5 MAR 22 LWPI reloaded  
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN  
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field  
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records  
NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records  
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN  
NEWS 12 MAY 01 New CAS web site launched  
NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined  
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields  
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data  
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload  
NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German patents  
NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents  
NEWS 19 JUN 27 CA/Caplus enhanced with pre-1967 CAS Registry Numbers  
NEWS 20 JUN 29 STN Viewer now available  
NEWS 21 JUN 29 STN Express, Version 8.2, now available  
NEWS 22 JUL 02 LEMBASE coverage updated  
NEWS 23 JUL 02 LMEDLINE coverage updated  
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names  
NEWS 25 JUL 02 CHEMCATS accession numbers revised  
NEWS 26 JUL 02 CA/Caplus enhanced with utility model patents from China  
NEWS 27 JUL 16 Caplus enhanced with French and German abstracts  
NEWS 28 JUL 18 CA/Caplus patent coverage enhanced  
  
NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:18:20 ON 20 JUL 2007

=> file polymer embase medline biosis  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.63	0.63

FULL ESTIMATED COST

FILE 'APOLLIT' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (c) 2007 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (c) 2007 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 11:20:12 ON 20 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (c) 2007 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 11:20:12 ON 20 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 11:20:12 ON 20 JUL 2007  
Compendex Compilation and Indexing (C) 2007  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 11:20:12 ON 20 JUL 2007  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2007)

FILE 'PASCAL' ENTERED AT 11:20:12 ON 20 JUL 2007  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 11:20:12 ON 20 JUL 2007  
Copyright (c) 2007 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 11:20:12 ON 20 JUL 2007  
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:20:12 ON 20 JUL 2007  
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 11:20:12 ON 20 JUL 2007  
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:20:12 ON 20 JUL 2007  
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 11:20:12 ON 20 JUL 2007

FILE 'BIOSIS' ENTERED AT 11:20:12 ON 20 JUL 2007  
Copyright (c) 2007 The Thomson Corporation

=> s composition  
19 FILES SEARCHED...  
L1 7433789 COMPOSITION

=> s l1 and (polysaccharide or dextran or starch or cellulose)  
23 FILES SEARCHED...  
L2 554816 L1 AND (POLYSACCHARIDE OR DEXTRAN OR STARCH OR CELLULOSE)

=> s l2 and ecapsul?  
L3 8 L2 AND ECAPSUL?

=> s l2 and encapsul?  
L4 69931 L2 AND ENCAPSUL?

=> s l4 and (EPO or erythropoietin or CSF or TPA or interferon or hormone or calcitonin or factor or protein or peptide)  
11 FILES SEARCHED...  
23 FILES SEARCHED...  
L5 55983 L4 AND (EPO OR ERYTHROPOIETIN OR CSF OR TPA OR INTERFERON OR HORMONE OR CALCITONIN OR FACTOR OR PROTEIN OR PEPTIDE)

=> s l5 and (PEG or PEO or PVP or PVA)  
L6 20251 L5 AND (PEG OR PEO OR PVP OR PVA)

=> s l6 and (solid(a)oil(a)water(a)emulsion)  
11 FILES SEARCHED...  
L7 0 L6 AND (SOLID(A) OIL(A) WATER(A) EMULSION)

=> s l6 and (method or process)  
6 FILES SEARCHED...  
10 FILES SEARCHED...  
15 FILES SEARCHED...  
L8 20192 L6 AND (METHOD OR PROCESS)

=> s 18 and (particles(w)diameter)  
22 FILES SEARCHED...  
L9 16 L8 AND (PARTICLES(W) DIAMETER)

=> dis 19 1-16 bib abs

L9 ANSWER 1 OF 16 USPATFULL on STN  
AN 2006:273983 USPATFULL  
TI Use of bacteriocin for the amelioration of digestive functionality  
IN Piva, Andrea, Bologna, ITALY  
Casadei, Gabriele, San Carlo Cesena (FC), ITALY  
PI US 2006233777 A1 20061019  
AI US 2004-551536 A1 20040325 (10)  
WO 2004-IB885 20040325  
20060605 PCT 371 date  
PRAI WO 2003-IT193 20030401  
DT Utility  
FS APPLICATION  
LREP PEARNE & GORDON LLP, 1801 EAST 9TH STREET, SUITE 1200, CLEVELAND, OH,  
44114-3108, US  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1-15  
DRWN No Drawings  
LN.CNT 783  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The subject of the present invention is the use of bacteriocins and/or  
their producer strains for the amelioration of digestive functionality  
and for the amelioration of gastrointestinal tract conditions in  
monogastric organism species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 16 USPATFULL on STN  
AN 2006:228410 USPATFULL  
TI Compositions and methods using same for treating  
amyloid-associated diseases  
IN Gazit, Ehud, Ramat-HaSharon, ISRAEL  
Porat, Yair, Hofit, ISRAEL  
PI US 2006194777 A1 20060831  
AI US 2006-386880 A1 20060323 (11)  
RLI Continuation-in-part of Ser. No. WO 2004-IL890, filed on 23 Sep 2004,  
UNKNOWN  
DT Utility  
FS APPLICATION  
LREP Martin D. MOYNIHAN, PRTSI, Inc., P.O. Box 16446, Arlington, VA, 22215,  
US  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Page(s)  
LN.CNT 2261  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds having one or more phenol moieties, derivatives thereof,  
compositions containing same and uses thereof for the treatment  
of amyloid-associated diseases are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 16 USPATFULL on STN  
AN 2006:174655 USPATFULL  
TI Detection of ion channel or receptor activity  
IN Marini, Davide, Brookline, MA, UNITED STATES  
Desai, Bimal, Arlington, MA, UNITED STATES  
Delling, Markus, Boston, MA, UNITED STATES

Solis, Daniel, Boston, MA, UNITED STATES  
Febvay, Sebastien, Cambridge, MA, UNITED STATES  
Carter, Brett, Brighton, MA, UNITED STATES  
Belcher, Angela, Lexington, MA, UNITED STATES  
Clapham, David, Wellesley, MA, UNITED STATES  
PA Massachusetts Institute of Technology (U.S. corporation)  
Children's Medical Center Corporation (U.S. corporation)  
PI US 2006148104 A1 20060706  
AI US 2005-264074 A1 20051031 (11)  
PRAI WO 2005-US39260 20051031  
US 2004-623334P 20041029 (60)  
DT Utility  
FS APPLICATION  
LREP CHOATE, HALL & STEWART LLP, TWO INTERNATIONAL PLACE, BOSTON, MA, 02110,  
US  
CLMN Number of Claims: 175  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Page(s)  
LN.CNT 5462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides nanosensors and nanosensor components for the detection of ion channel activity, receptor activity, or protein protein interactions. Certain of the nanosensor components comprise a nanoparticle and recognition domain. Following contact with cells and, optionally, internalization of the nanosensor component by a cell, the recognition domain binds to a target domain, e.g., a heterologous target domain, of a polypeptide of interest such as an ion channel subunit, G protein coupled receptor (GPCR), or G protein subunit. Ion channel activity, GPCR activity, or altered protein interaction results in a detectable signal. The nanoparticles may be functionalized so that they respond to the presence of an ion by altering their proximity. Certain of the nanosensors utilize the phenomenon of plasmon resonance to produce a signal while others utilize magnetic properties, RET, and/or ion-sensitive moieties. Also provided are polypeptides, e.g., ion channel subunits, comprising a heterologous target domain, and cell lines that express the polypeptides. Further provided are a variety of methods for detecting ion channel activity, receptor activity, or protein interaction and for identifying compounds that modulate one or more of these. In certain embodiments the invention allows the user to detect the activity of specific ion channels even in the presence of other channels that permit passage of the same ion(s) or result in activation of the same downstream targets, thereby achieving improved specificity in high throughput screens while at the same time providing a high signal to noise ratio.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 16 USPATFULL on STN  
AN 2006:166403 USPATFULL  
TI Central airway administration for systemic delivery of therapeutics  
IN Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES  
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES  
Simister, Neil E., Wellesley, MA, UNITED STATES  
Bitonti, Alan J., Acton, MA, UNITED STATES  
PI US 2006140907 A1 20060629  
AI US 2006-336581 A1 20060120 (11)  
RLI Continuation of Ser. No. US 2003-435608, filed on 9 May 2003, PENDING  
Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002,  
PENDING  
PRAI US 2002-364482P 20020315 (60)  
DT Utility  
FS APPLICATION  
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,

BOSTON, MA, 02210-2206, US  
CLMN Number of Claims: 51  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Page(s)  
LN.CNT 3829

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 16 USPATFULL on STN  
AN 2005:68465 USPATFULL  
TI Drug delivery system based on polymer nanoshells  
IN Gao, Jinming, Pepper Pike, OH, UNITED STATES  
Ai, Hua, Cleveland, OH, UNITED STATES  
PA Case Western Reserve University, Cleveland, OH (U.S. corporation)  
PI US 2005058603 A1 20050317  
AI US 2004-838289 A1 20040503 (10)  
PRAI US 2003-502429P 20030912 (60)  
US 2003-467389P 20030502 (60)  
DT Utility  
FS APPLICATION  
LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Page(s)  
LN.CNT 5026

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to polymeric nanoshells. In certain embodiments, the polymeric nanoshells comprise one or more polymeric shells around a hollow core. In other embodiments, the present invention provides nanoshells useful for the delivery of agents such as, for example, various diagnostic and therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 16 USPATFULL on STN  
AN 2005:66053 USPATFULL  
TI Printing plate material and printing process  
IN Mori, Takahiro, Tokyo, JAPAN  
PA KONICA MINOLTA MEDICAL & GRAPHIC, INC. (non-U.S. corporation)  
PI US 2005056179 A1 20050317  
US 7107905 B2 20060919  
AI US 2004-938889 A1 20040913 (10)  
PRAI JP 2003-324234 20030917  
DT Utility  
FS APPLICATION  
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1622

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a printing plate material comprising a support and provided thereon, a hydrophilic layer containing pigment particles having a light-to-heat conversion capability, wherein the pigment particles have an average particle diameter of from 0.15  $\mu\text{m}$  to less than 1.0  $\mu\text{m}$ , and the hydrophilic layer has a surface roughness Ra of from 0.2  $\mu\text{m}$  to less than 1.5  $\mu\text{m}$ .

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 16 USPATFULL on STN  
AN 2004:215210 USPATFULL  
TI Iridescent pigment having high brilliance and high chroma  
IN Noguchi, Tamio, Fukushima-ken, JAPAN  
PI US 2004166316 A1 20040826  
US 7241503 B2 20070710  
AI US 2003-717926 A1 20031121 (10)  
PRAI JP 2002-338344 20021121  
DT Utility  
FS APPLICATION  
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE  
1400, ARLINGTON, VA, 22201  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1380

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An iridescent multilayer pigment having at least two or more layers of metal oxides containing one or more metals selected from Ce, Sn, Ti, Fe, Zn and Zr which are coated onto the surface of thin platelet-like substrates. The inventive pigments show high brilliance and high chroma, in particular in cases in which thin platelet-like substrates having a fine average particle diameter are used. The pigment is useful in paints, printing inks, lacquers, plastics, dopants for laser marking, non-dusting pigment products, non-dusting pigment granules or cosmetics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 16 USPATFULL on STN  
AN 2004:83456 USPATFULL  
TI Central airway administration for systemic delivery of therapeutics  
IN Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES  
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES  
Simister, Neil E., Wellesley, MA, UNITED STATES  
Bitonti, Alan J., Acton, MA, UNITED STATES  
PA The Brigham and Women's Hospital, Inc., Boston, MA (U.S. corporation)  
Children's Medical Center Corporation, Boston, MA (U.S. corporation)  
Brandeis University, Waltham, MA (U.S. corporation)  
Syntonix Pharmaceuticals, Inc., Waltham, MA (U.S. corporation)  
PI US 2004063912 A1 20040401  
AI US 2003-622108 A1 20030717 (10)  
RLI Continuation-in-part of Ser. No. US 2003-435608, filed on 9 May 2003,  
PENDING Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul  
2002, PENDING  
PRAI US 2002-364482P 20020315 (60)  
DT Utility  
FS APPLICATION  
LREP Alan W. Steele, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue,  
Boston, MA, 02210  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Page(s)  
LN.CNT 4477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and products for the

transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long. In one embodiment the fusion protein includes an interferon-alpha 2b (IFN- $\alpha$ 2b) joined at its C terminal end through a peptide linker having a sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29) to the N terminal end of a human Fc $\gamma$ 1 heavy chain. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 16 USPATFULL on STN  
AN 2003:334661 USPATFULL  
TI Central airway administration for systemic delivery of therapeutics  
IN Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES  
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES  
Simister, Neil E., Wellesley, MA, UNITED STATES  
Bitonti, Alan J., Acton, MA, UNITED STATES  
PA The Brigham and Women's Hospital, Inc., Boston, MA, UNITED STATES, 02115  
(U.S. corporation)  
Children's Medical Center Corporation, Boston, MA, UNITED STATES, 02115  
(U.S. corporation)  
Brandeis University, Waltham, MA, UNITED STATES, 02254 (U.S.  
corporation)  
Syntonix Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S.  
corporation)  
PI US 2003235536 A1 20031225  
AI US 2003-435608 A1 20030509 (10)  
RLI Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002,  
PENDING  
PRAI US 2002-364482P 20020315 (60)  
DT Utility  
FS APPLICATION  
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,  
BOSTON, MA, 02210-2211  
CLMN Number of Claims: 127  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Page(s)  
LN.CNT 4042

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 16 USPATFULL on STN  
AN 2003:244817 USPATFULL  
TI Isotropic cleansing composition with benefit agent particles  
IN Shana'a, May, Trumbull, CT, UNITED STATES  
Villa, Virgilio Barba, Emerson, NJ, UNITED STATES  
PA Unilever Home and Personal Care USA, Division of Conopco, Inc. (U.S. corporation)  
PI US 2003171230 A1 20030911  
US 6737394 B2 20040518  
AI US 2002-90086 A1 20020304 (10)  
DT Utility  
FS APPLICATION  
LREP UNILEVER, PATENT DEPARTMENT, 45 RIVER ROAD, EDGEWATER, NJ, 07020  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1478

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous isotropic liquid cleansing and moisturizing composition is provided having a surfactant; a thickening agent, and organogel particles with a structure comprising a benefit agent and a gellation agent. In a preferred embodiment the inventive cleansing composition includes a free emollient having a weight average emollient particle size in the range about 1 to about 500 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 16 USPATFULL on STN  
AN 2002:236027 USPATFULL  
TI Methods and products related to pulmonary delivery of polysaccharides  
IN Liu, Dongfang, Framingham, MA, UNITED STATES  
Qi, Yiwei, Framingham, MA, UNITED STATES  
Venkataraman, Ganesh, Woburn, MA, UNITED STATES  
Sundaram, Mallikarjun, Brighton, MA, UNITED STATES  
Sasisekharan, Ram, Cambridge, MA, UNITED STATES  
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)  
PI US 2002128225 A1 20020912  
AI US 2001-982548 A1 20011018 (9)  
PRAI US 2000-241559P 20001018 (60)  
DT Utility  
FS APPLICATION  
LREP Helen C. Lockhart, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 2380

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods for delivering polysaccharides by a pulmonary route to achieve local and systemic therapeutic effects. The polysaccharides may be formulated or unformulated and in some instances have an extremely fast absorption rate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 16 USPATFULL on STN  
AN 2002:119885 USPATFULL  
TI Spontaneously dispersible N-benzoyl staurosporine compositions  
IN Matthews, Graham Paul, Horsham, UNITED KINGDOM

Haeberlin, Barbara, Munchenstein, SWITZERLAND  
PI US 2002061873 A1 20020523  
AI US 2001-930335 A1 20010815 (9)  
RLI Continuation of Ser. No. WO 2000-EP1196, filed on 14 Feb 2000, UNKNOWN  
PRAI GB 1999-3547 19990216  
DT Utility  
FS APPLICATION  
LREP THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564  
MORRIS AVENUE, SUMMIT, NJ, 079011027  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 849

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 16 USPAT2 on STN  
AN 2005:66053 USPAT2  
TI Printing plate material and printing process  
IN Mori, Takahiro, Hachioji, JAPAN  
PA Konica Minolta Medical & Graphic, Inc., Tokyo, JAPAN (non-U.S. corporation)  
PI US 7107905 B2 20060919  
AI US 2004-938889 20040913 (10)  
PRAI JP 2003-324234 20030917  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Colilia, Daniel J.; Assistant Examiner: Culler, Jill E.  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1598

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a printing plate material comprising a support and provided thereon, a hydrophilic layer containing pigment particles having a light-to-heat conversion capability, wherein the pigment particles have an average particle diameter of from 0.15  $\mu\text{m}$  to less than 1.0  $\mu\text{m}$ , and the hydrophilic layer has a surface roughness Ra of from 0.2  $\mu\text{m}$  to less than 1.5  $\mu\text{m}$ .

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 16 USPAT2 on STN  
AN 2004:215210 USPAT2  
TI Iridescent pigment having high brilliance and high chroma  
IN Noguchi, Tamio, Fukushima-ken, JAPAN  
PA Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)  
PI US 7241503 B2 20070710  
AI US 2003-717926 20031121 (10)  
PRAI JP 2002-338344 20021121  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Le, H. Thi  
LREP Millen, White, Zelano & Branigan, P.C.  
CLMN Number of Claims: 28

ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1386

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An iridescent multilayer pigment having at least two or more layers of metal oxides containing one or more metals selected from Ce, Sn, Ti, Fe, Zn and Zr which are coated onto the surface of thin platelet-like substrates. The inventive pigments show high brilliance and high chroma, in particular in cases in which thin platelet-like substrates having a fine average particle diameter are used. The pigment is useful in paints, printing inks, lacquers, plastics, dopants for laser marking, non-dusting pigment products, non-dusting pigment granules or cosmetics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 16 USPAT2 on STN  
AN 2004:77318 USPAT2  
TI Biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere  
IN Phillips, Glyn Owen, Cardiff, UNITED KINGDOM  
Du Plessis, Tjaart Andries, Pretoria, SOUTH AFRICA  
Al-Assaf, Saphwan, Wrexham, UNITED KINGDOM  
Williams, Peter Anthony, Cardiff, UNITED KINGDOM  
PA Phillips Hydrocolloids Research Limited, London, UNITED KINGDOM (non-U.S. corporation)  
PI US 6841644 B2 20050111  
AI US 2003-400632 20030328 (10)  
RLI Division of Ser. No. US 2001-805385, filed on 13 Mar 2001, now patented, Pat. No. US 6610810  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Nutter, Nathan M.  
LREP Galvin & Palmer, Palmer, Sheldon  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 41 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 1416

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are modified naturally occurring biocompatible biopolymers of plant and animal origin made by subjecting same to ionizing radiation in the presence of a mediating gas, typically acetylene to enable one to selectively enhance and modify one or more of the physiochemical properties of the starting materials which have a wide range of uses in medicine, food technology and other industrial applications. Notwithstanding the modifications, the biocompatibility of the biopolymer remains unchanged and no new or additional functional groups are introduced into the starting biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 16 USPAT2 on STN  
AN 2003:244817 USPAT2  
TI Isotropic cleansing composition with benefit agent particles  
IN Shana'a, May, Trumbull, CT, United States  
Villa, Virgilio Barba, Emerson, NJ, United States  
PA Unilever Home & Personal Care USA, division of Conopco, Inc., Greenwich, CT, United States (U.S. corporation)  
PI US 6737394 B2 20040518  
AI US 2002-90086 20020304 (10)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Hardee, John R.  
LREP Bornstein, Alan A.  
CLMN Number of Claims: 27

ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1436

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous isotropic liquid cleansing and moisturizing composition is provided having a surfactant; a thickening agent, and organogel particles with a structure comprising a benefit agent and a gellation agent. In a preferred embodiment the inventive cleansing composition includes a free emollient having a weight average emollient particle size in the range about 1 to about 500 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 16 and microsphere  
L10 7614 L6 AND MICROSPHERE

=> s 110 and chitosan  
L11 1444 L10 AND CHITOSAN

=> s 111 and drug  
22 FILES SEARCHED...  
L12 1338 L11 AND DRUG

=> s 112 and (prednisolone or cortisone)  
L13 405 L12 AND (PREDNISOLONE OR CORTISONE)

=> s 113 and (cellulose(a)acetate)  
L14 236 L13 AND (CELLULOSE(A) ACETATE)

=> s 114 and (sustained(a)release)  
L15 181 L14 AND (SUSTAINED(A) RELEASE)

=> s 115 and (aqueous(w) suspension)  
L16 83 L15 AND (AQUEOUS(W) SUSPENSION)

=> dis 116 1-83 bib abs

L16 ANSWER 1 OF 83 USPATFULL on STN

AN 2007:184697 USPATFULL

TI Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

IN Castro, Alfredo C., Winchester, MA, UNITED STATES

Holson, Edward B., Newton Highlands, MA, UNITED STATES

Hopkins, Brian T., Brookline, MA, UNITED STATES

Koney, Nii O., Brighton, MA, UNITED STATES

Snyder, Daniel A., Cambridge, MA, UNITED STATES

Tibbitts, Thomas T., Westford, MA, UNITED STATES

PA Infinity Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

PI US 2007161690 A1 20070712

AI US 2006-600332 A1 20061115 (11)

RLI Continuation-in-part of Ser. No. US 2005-156364, filed on 17 Jun 2005, PENDING

PRAI US 2004-580616P 20040617 (60)

US 2005-659301P 20050307 (60)

DT Utility

FS APPLICATION

LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2349

AB One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

L16 ANSWER 2 OF 83 USPATFULL on STN

AN 2007:106584 USPATFULL

TI Compositions and methods of making rapidly dissolving ionically masked formulations

IN Tengler, Mark, Colleyville, TX, UNITED STATES

McMahen, Russell Lee, Flower Mound, TX, UNITED STATES

PA Pfab LP, Grand Prairie, TX, UNITED STATES (U.S. corporation)

PI US 2007092553 A1 20070426

AI US 2005-255555 A1 20051021 (11)

DT Utility

FS APPLICATION

LREP CHALKER FLORES, LLP, 2711 LBJ FRWY, Suite 1036, DALLAS, TX, 75234, US

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1851

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 83 USPATFULL on STN

AN 2007:62144 USPATFULL

TI Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

IN Manoharan, Muthiah, Weston, MA, UNITED STATES

Rajeev, Kallanthottathil G., Cambridge, MA, UNITED STATES

Xia, Jie, Carlsbad, CA, UNITED STATES

PA Alnylam Pharmaceuticals, Cambridge, MA, UNITED STATES (U.S. corporation)

PI US 2007054279 A1 20070308

AI US 2005-197753 A1 20050804 (11)

PRAI US 2004-598596P 20040804 (60)

DT Utility

FS APPLICATION

LREP FOLEY HOAG, LLP, PATENT GROUP (w/APX), 155 SEAPORT BLVD, BOSTON, MA, 02210-2600, US

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN 39 Drawing Page(s)

LN.CNT 7590

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands

comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 83 USPATFULL on STN  
 AN 2007:12286 USPATFULL  
 TI Medical device with low magnetic susceptibility  
 IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
 Greenwald, Howard J., Rochester, NY, UNITED STATES  
 PI US 2007010702 A1 20070111  
 AI US 2005-171761 A1 20050630 (11)  
 RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, GRANTED, Pat. No. US 7091412 Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, ABANDONED Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, GRANTED, Pat. No. US 6914412 Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609  
 DT Utility  
 FS APPLICATION  
 LREP CURATOLO SIDOTI CO., LPA, 24500 CENTER RIDGE ROAD, SUITE 280, CLEVELAND, OH, 44145, US  
 CLMN Number of Claims: 315  
 ECL Exemplary Claim: 1  
 DRWN 54 Drawing Page(s)  
 LN.CNT 18747  
 AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a direct or alternating current magnetic susceptibility within the range of from about plus 1+10.sup.-2 centimeter-gram-seconds to about minus 1+10.sup.-2 centimeter-gram-seconds.

L16 ANSWER 5 OF 83 USPATFULL on STN  
 AN 2007:12087 USPATFULL  
 TI Methods and reagents for the treatment of immunoinflammatory disorders  
 IN Keith, Curtis, Boston, MA, UNITED STATES  
 Borisy, Alexis, Arlington, MA, UNITED STATES  
 Zimmermann, Grant R., Somerville, MA, UNITED STATES  
 Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES  
 Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES  
 Hurst, Nicole, Boston, MA, UNITED STATES  
 Foley, Michael A., Chestnut Hill, MA, UNITED STATES

Slavonic, Michael S., Quincy, MA, UNITED STATES  
Smith, Brendan, Somerville, MA, UNITED STATES  
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES  
PA CombinatoRx Inc., Cambridge, MA, UNITED STATES (U.S. corporation)  
PI US 2007010502 A1 20070111  
AI US 2006-517593 A1 20060907 (11)  
RLI Continuation of Ser. No. US 2004-966228, filed on 15 Oct 2004, PENDING  
PRAI US 2003-512415P 20031015 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4260

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 83 USPATFULL on STN

AN 2006:334645 USPATFULL  
TI Oligonucleotides comprising a non-phosphate backbone linkage  
IN Manoharan, Muthiah, Weston, MA, UNITED STATES  
Rajeev, Kallanthottathil G., Cambridge, MA, UNITED STATES  
PA Alnylam Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)  
PI US 2006287260 A1 20061221  
AI US 2005-170798 A1 20050629 (11)  
PRAI US 2004-584061P 20040630 (60)  
US 2004-614528P 20040930 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 9371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3'-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate,

hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 83 USPATFULL on STN  
AN 2006:333565 USPATFULL  
TI Methods and reagents for the treatment of inflammatory disorders  
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES  
Nolan, Garry, Brookline, MA, UNITED STATES  
Zimmermann, Grant R., Somerville, MA, UNITED STATES  
PA CombinatoRx, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)  
PI US 2006286177 A1 20061221  
AI US 2006-454559 A1 20060616 (11)  
PRAI US 2005-691953P 20050617 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2519

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering bufexamac and a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing bufexamac and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 83 USPATFULL on STN  
AN 2006:328918 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2006282123 A1 20061214  
AI US 2004-6910 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-2264  
DRWN 32 Drawing Page(s)  
LN.CNT 14774

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L16 ANSWER 9 OF 83 USPATFULL on STN

AN 2006:28626 USPATFULL

TI Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

IN Castro, Alfredo C., Winchester, MA, UNITED STATES

Deng, Wei, Lexington, MA, UNITED STATES

Depew, Kristopher M., Acton, MA, UNITED STATES

Foley, Michael A., Chestnut Hill, MA, UNITED STATES

Fritz, Christian C., Natick, MA, UNITED STATES

Georges Evangelinos, Asimina T., Andover, MA, UNITED STATES

Grogan, Michael J., Arlington, MA, UNITED STATES

Hafeez, Nafeeza, West Roxbury, MA, UNITED STATES

Holson, Edward B., Newton Highlands, MA, UNITED STATES

Hopkins, Brian T., Brookline, MA, UNITED STATES

Koney, Nii O., Somerville, MA, UNITED STATES

Liu, Tao, Ashland, MA, UNITED STATES

Mann, David A., Swampscott, MA, UNITED STATES

Marcaurette, Lisa A., Arlington, MA, UNITED STATES

Snyder, Daniel A., Cambridge, MA, UNITED STATES

Underwood, Dennis J., Jamaica Plain, MA, UNITED STATES

Wylie, Andrew A., Brookline, MA, UNITED STATES

Yu, Lin-Chen, Wollaston, MA, UNITED STATES

Zhang, Linping, Lexington, MA, UNITED STATES

PA Infinity Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

PI US 2006025460 A1 20060202

AI US 2005-156364 A1 20050617 (11)

PRAI US 2004-580616P 20040617 (60)

US 2005-659301P 20050307 (60)

DT Utility

FS APPLICATION

LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 6924

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 83 USPATFULL on STN

AN 2006:10579 USPATFULL

TI Nitrosated and nitrosylated compounds, compositions and methods use

IN Earl, Richard A., Westford, MA, UNITED STATES

Garvey, David S., Dover, MA, UNITED STATES

Gaston, Ricky D., Malden, MA, UNITED STATES

Lin, Chia-En, Concord, MA, UNITED STATES

Ranatunge, Ramani R., Lexington, MA, UNITED STATES

Richardson, Stewart K., Tolland, CT, UNITED STATES

Stevenson, Cheri A., Haverhill, MA, UNITED STATES  
PA NitroMed, Inc., Lexington, MA, UNITED STATES (U.S. corporation)  
PI US 2006009431 A1 20060112  
AI US 2005-221901 A1 20050909 (11)  
RLI Continuation of Ser. No. WO 2004-US7943, filed on 15 Mar 2004, PENDING  
PRAI US 2003-453963P 20030313 (60)  
US 2003-482134P 20030625 (60)  
DT Utility  
FS APPLICATION  
LREP EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON,  
DC, 20004, US  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratrol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 83 USPATFULL on STN  
AN 2005:331259 USPATFULL  
TI Oligonucleotides comprising a C5-modified pyrimidine  
IN Manoharan, Muthiah, Weston, MA, UNITED STATES  
Rajeev, Kallanthottathil G., Cambridge, MA, UNITED STATES  
PA Alnylam Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02142 (U.S. corporation)  
PI US 2005288244 A1 20051229  
AI US 2005-119533 A1 20050429 (11)  
PRAI US 2004-566710P 20040430 (60)  
US 2004-620276P 20041020 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY HOAG LLP, 155 SEAPORT BLVD - SEAPORT WORLD TRADE CENTER WEST,  
BOSTON, MA, 02210-2600, US  
CLMN Number of Claims: 52  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Page(s)  
LN.CNT 6466

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5 $\beta$ -cholanic acid. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5 $\beta$ -cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 83 USPATFULL on STN

AN 2005:318834 USPATFULL

TI Compositions and methods for treating diverticular disease

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005277577 A1 20051215

US 7241736 B2 20070710

AI US 2005-129763 A1 20050512 (11)

RLI Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 56

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 10081

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 83 USPATFULL on STN

AN 2005:241661 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toliekis, Philip M., Vancouver, CANADA  
    Maiti, Arpita, Vancouver, CANADA  
PA    Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI    US 2005209666            A1    20050922  
AI    US 2004-6885            A1    20041207 (11)  
RLI    Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI  US 2004-586861P          20040709 (60)  
US 2004-578471P          20040609 (60)  
US 2003-526541P          20031203 (60)  
US 2003-525226P          20031124 (60)  
US 2003-523908P          20031120 (60)  
US 2003-524023P          20031120 (60)  
DT    Utility  
FS    APPLICATION  
LREP  SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN  Number of Claims: 112  
ECL    Exemplary Claim: 1-630  
DRWN  32 Drawing Page(s)  
LN.CNT 14772  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB    Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 14 OF 83  USPATFULL on STN  
AN    2005:241660  USPATFULL  
TI    Electrical devices and anti-scarring agents  
IN    Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toliekis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA    Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI    US 2005209665            A1    20050922  
AI    US 2004-998351            A1    20041126 (10)  
RLI    Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov  
2004, PENDING  
PRAI  US 2004-586861P          20040709 (60)  
US 2004-578471P          20040609 (60)  
US 2003-526541P          20031203 (60)  
US 2003-525226P          20031124 (60)  
US 2003-523908P          20031120 (60)  
US 2003-524023P          20031120 (60)  
DT    Utility  
FS    APPLICATION  
LREP  SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN  Number of Claims: 112  
ECL    Exemplary Claim: 1-11691  
DRWN  32 Drawing Page(s)  
LN.CNT 14777  
AB    Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within

an animal.

L16 ANSWER 15 OF 83 USPATFULL on STN  
AN 2005:241659 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005209664 A1 20050922  
AI US 2004-998349 A1 20041126 (10)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586471P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-1377  
DRWN 32 Drawing Page(s)  
LN.CNT 14786  
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

L16 ANSWER 16 OF 83 USPATFULL on STN  
AN 2005:240095 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005208095 A1 20050922  
AI US 2004-996354 A1 20041122 (10)  
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 101

ECL Exemplary Claim: 1  
DRWN 32 Drawing Page(s)  
LN.CNT 34089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 83 USPATFULL on STN

AN 2005:234693 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005203635 A1 20050915

AI US 2004-6909 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 76

ECL Exemplary Claim: 1-3038

DRWN 32 Drawing Page(s)

LN.CNT 12596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 83 USPATFULL on STN

AN 2005:226572 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005196421 A1 20050908

AI US 2004-1417 A1 20041201 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 100  
ECL Exemplary Claim: 1-7300  
DRWN 32 Drawing Page(s)  
LN.CNT 34222  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compositions comprising anti-fibrotic agent(s) and/or  
polymeric compositions can be used in various medical  
applications including the prevention of surgical adhesions, treatment  
of inflammatory arthritis, treatment of scars and keloids, the treatment  
of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 83 USPATFULL on STN  
AN 2005:221910 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005192647 A1 20050901  
AI US 2004-6898 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-1992  
DRWN 32 Drawing Page(s)  
LN.CNT 14794  
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

L16 ANSWER 20 OF 83 USPATFULL on STN  
AN 2005:215962 USPATFULL  
TI Soft tissue implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)  
 PI US 2005187639 A1 20050825  
 AI US 2004-6892 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 101  
 ECL Exemplary Claim: 1-3470  
 DRWN 32 Drawing Page(s)  
 LN.CNT 12657  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
 nasal implants) are used in combination with an anti-scarring agent in  
 order to inhibit scarring that may otherwise occur when the implant is  
 placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 83 USPATFULL on STN  
 AN 2005:215923 USPATFULL  
 TI Electrical devices and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)  
 PI US 2005187600 A1 20050825  
 AI US 2004-998350 A1 20041126 (10)  
 RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-3352  
 DRWN 32 Drawing Page(s)  
 LN.CNT 14781  
 AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
 devices) for contact with tissue are used in combination with an  
 anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit

scarring that may otherwise occur when the devices are implanted within an animal.

L16 ANSWER 22 OF 83 USPATFULL on STN

AN 2005:215527 USPATFULL

TI Methods and reagents for the treatment of inflammatory disorders

IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES

Manivasakam, Palaniyandi, Brighton, MA, UNITED STATES

Smith, Brendan, Boston, MA, UNITED STATES

Slavonic, Michael S., Quincy, MA, UNITED STATES

Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

PI US 2005187203 A1 20050825

AI US 2004-992878 A1 20041119 (10)

PRAI US 2003-524117P 20031121 (60)

DT Utility

FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2781

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 83 USPATFULL on STN

AN 2005:215524 USPATFULL

TI Methods and reagents for the treatment of inflammatory disorders

IN Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

Borisy, Alexis, Arlington, MA, UNITED STATES

Fong, Jason, Philadelphia, PA, UNITED STATES

Hurst, Nicole, Boston, MA, UNITED STATES

Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES

Keith, Curtis T., Boston, MA, UNITED STATES

Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES

Sackeyfio, Robyn, Ann Arbor, MI, UNITED STATES

Slavonic, Michael S., Quincy, MA, UNITED STATES

Smith, Brendan, Boston, MA, UNITED STATES

Zimmermann, Grant R., Somerville, MA, UNITED STATES

PI US 2005187200 A1 20050825

AI US 2004-987554 A1 20041112 (10)

PRAI US 2003-520446P 20031113 (60)

DT Utility

FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a tricyclic compound and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing a tricyclic compound and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 83 USPATFULL on STN  
AN 2005:215464 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005187140 A1 20050825  
AI US 2004-408 A1 20041129 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2004-611077P 20040917 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 103  
ECL Exemplary Claim: 1-5846  
DRWN 32 Drawing Page(s)  
LN.CNT 34103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or  
polymeric compositions can be used in various medical  
applications including the prevention of surgical adhesions, treatment  
of inflammatory arthritis, treatment of scars and keloids, the treatment  
of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 83 USPATFULL on STN  
AN 2005:214574 USPATFULL  
TI Soft tissue implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005186246 A1 20050825  
AI US 2004-6883 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility

FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 101  
ECL Exemplary Claim: 1-2606  
DRWN 32 Drawing Page(s)  
LN.CNT 12658  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 83 USPATFULL on STN  
AN 2005:214573 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005186245 A1 20050825  
AI US 2004-6880 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-2785  
DRWN 32 Drawing Page(s)  
LN.CNT 15059  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 83 USPATFULL on STN  
AN 2005:214572 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005186244 A1 20050825

AI US 2004-1790 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 103  
ECL Exemplary Claim: 1-8540  
DRWN 32 Drawing Page(s)  
LN.CNT 34060  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compositions comprising anti-fibrotic agent(s) and/or  
polymeric compositions can be used in various medical  
applications including the prevention of surgical adhesions, treatment  
of inflammatory arthritis, treatment of scars and keloids, the treatment  
of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 83 USPATFULL on STN  
AN 2005:214567 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005186239 A1 20050825  
AI US 2004-6897 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-3058  
DRWN 32 Drawing Page(s)  
LN.CNT 15050  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 29 OF 83 USPATFULL on STN

AN 2005:212068 USPATFULL  
 TI Polymer compositions and methods for their use  
 IN Hunter, William L., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 Takacs-Cox, Aniko, North Vancouver, CANADA  
 Avelar, Rui, Vancouver, CANADA  
 Loss, Troy A.E., North Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 2005183731 A1 20050825  
 AI US 2004-6908 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING  
 PRAI US 2004-611077P 20040917 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-566569P 20040428 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 52  
 ECL Exemplary Claim: 1-8061  
 DRWN 32 Drawing Page(s)  
 LN.CNT 34032  
 AB Compositions comprising anti-fibrotic agent(s) and/or  
 polymeric compositions can be used in various medical  
 applications including the prevention of surgical adhesions, treatment  
 of inflammatory arthritis, treatment of scars and keloids, the treatment  
 of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 30 OF 83 USPATFULL on STN  
 AN 2005:210011 USPATFULL  
 TI Soft tissue implants and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 2005182496 A1 20050818  
 AI US 2004-6906 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 76  
 ECL Exemplary Claim: 1-3902  
 DRWN 32 Drawing Page(s)

LN.CNT 12588

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 31 OF 83 USPATFULL on STN

AN 2005:209984 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

PI US 2005182469 A1 20050818

AI US 2004-7837 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 120

ECL Exemplary Claim: 1-2803

DRWN 32 Drawing Page(s)

LN.CNT 14838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 32 OF 83 USPATFULL on STN

AN 2005:209983 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005182468 A1 20050818

AI US 2004-6891 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-1720  
DRWN 32 Drawing Page(s)  
LN.CNT 14768  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 33 OF 83 USPATFULL on STN  
AN 2005:209982 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005182467 A1 20050818  
AI US 2004-6884 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-1168  
DRWN 32 Drawing Page(s)  
LN.CNT 14785  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 34 OF 83 USPATFULL on STN  
AN 2005:209978 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA  
 Takacs-Cox, Aniko, North Vancouver, CANADA  
 Avelar, Rui, Vancouver, CANADA  
 Loss, Troy A. E., North Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)  
 PI US 2005182463 A1 20050818  
 AI US 2004-1788 A1 20041202 (11)  
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
 PRAI US 2004-611077P 20040917 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-566569P 20040428 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 125  
 ECL Exemplary Claim: 1-8059  
 DRWN 32 Drawing Page(s)  
 LN.CNT 34070  
 AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 35 OF 83 USPATFULL on STN  
 AN 2005:209965 USPATFULL  
 TI Electrical devices and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 2005182450 A1 20050818  
 AI US 2004-6890 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-349  
 DRWN 32 Drawing Page(s)  
 LN.CNT 14792  
 AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within

an animal.

L16 ANSWER 36 OF 83 USPATFULL on STN  
AN 2005:208532 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005181010 A1 20050818  
AI US 2004-1789 A1 20041201 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 109  
ECL Exemplary Claim: 1-296  
DRWN 32 Drawing Page(s)  
LN.CNT 15014  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 83 USPATFULL on STN  
AN 2005:208531 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005181009 A1 20050818  
AI US 2004-1787 A1 20041201 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 110

ECL Exemplary Claim: 1-570

DRWN 32 Drawing Page(s)

LN.CNT 15035

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 83 USPATFULL on STN

AN 2005:208529 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005181007 A1 20050818

AI US 2004-1415 A1 20041130 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 126

ECL Exemplary Claim: 1-444

DRWN 32 Drawing Page(s)

LN.CNT 12675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 83 USPATFULL on STN

AN 2005:208527 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.  
corporation)

PI US 2005181005 A1 20050818

AI US 2004-6901 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-2510  
DRWN 32 Drawing Page(s)  
LN.CNT 15035  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 40 OF 83 USPATFULL on STN  
AN 2005:205930 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005178396 A1 20050818  
AI US 2004-6905 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1-8063  
DRWN 32 Drawing Page(s)  
LN.CNT 33965  
AB Compositions comprising anti-fibrotic agent(s) and/or  
polymeric compositions can be used in various medical  
applications including the prevention of surgical adhesions, treatment  
of inflammatory arthritis, treatment of scars and keloids, the treatment  
of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 41 OF 83 USPATFULL on STN  
AN 2005:205929 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 Takacs-Cox, Aniko, North Vancouver, CANADA  
 Avelar, Rui, Vancouver, CANADA  
 Loss, Troy A. E., North Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 2005178395 A1 20050818  
 AI US 2004-6900 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING  
 PRAI US 2004-611077P 20040917 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-566569P 20040428 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 58  
 ECL Exemplary Claim: 1-7302  
 DRWN 32 Drawing Page(s)  
 LN.CNT 34043  
 AB Compositions comprising anti-fibrotic agent(s) and/or  
 polymeric compositions can be used in various medical  
 applications including the prevention of surgical adhesions, treatment  
 of inflammatory arthritis, treatment of scars and keloids, the treatment  
 of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 42 OF 83 USPATFULL on STN  
 AN 2005:202285 USPATFULL  
 TI Polymer compositions and methods for their use  
 IN Hunter, William L., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 Takacs-Cox, Aniko, North Vancouver, CANADA  
 Avelar, Rui, Vancouver, CANADA  
 Loss, Troy A.E., North Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 2005175703 A1 20050811  
 AI US 2004-6888 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING  
 PRAI US 2004-611077P 20040917 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-566569P 20040428 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 55  
 ECL Exemplary Claim: 1-7576  
 DRWN 32 Drawing Page(s)  
 LN.CNT 33992  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 83 USPATFULL on STN

AN 2005:202247 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005175665 A1 20050811

AI US 2004-6896 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING

PRAI US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 51

ECL Exemplary Claim: 1-7822

DRWN 32 Drawing Page(s)

LN.CNT 33978

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 83 USPATFULL on STN

AN 2005:202246 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005175664 A1 20050811

AI US 2004-4672 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov

2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 109

ECL Exemplary Claim: 1-851

DRWN 32 Drawing Page(s)

LN.CNT 15038

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 83 USPATFULL on STN

AN 2005:195820 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005169961 A1 20050804

AI US 2004-4675 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 118

ECL Exemplary Claim: 1-1941

DRWN 32 Drawing Page(s)

LN.CNT 15063

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 46 OF 83 USPATFULL on STN

AN 2005:195819 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.)

corporation)  
PI US 2005169960 A1 20050804  
AI US 2004-4671 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 110  
ECL Exemplary Claim: 1-3328  
DRWN 32 Drawing Page(s)  
LN.CNT 15057

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 47 OF 83 USPATFULL on STN  
AN 2005:182973 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005158356 A1 20050721  
AI US 2004-996352 A1 20041122 (10)  
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 117  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Page(s)  
LN.CNT 15058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 83 USPATFULL on STN  
AN 2005:178293 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005154374 A1 20050714  
AI US 2004-6882 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-2240  
DRWN 32 Drawing Page(s)  
LN.CNT 15052  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 49 OF 83 USPATFULL on STN  
AN 2005:177866 USPATFULL  
TI Methods and reagents for the treatment of diseases and disorders  
associated with increased levels of proinflammatory cytokines  
IN Padval, Mahesh, Waltham, MA, UNITED STATES  
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES  
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES  
Smith, Brendan, Boston, MA, UNITED STATES  
Fong, Jason, Philadelphia, PA, UNITED STATES  
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES  
Nichols, M. James, Boston, MA, UNITED STATES  
Keith, Curtis, Boston, MA, UNITED STATES  
Zimmerman, Grant R., Somerville, MA, UNITED STATES  
Brasher, Bradley B., Natick, MA, UNITED STATES  
Sachs, Noah, Boston, MA, UNITED STATES  
Chappell, Todd W., Boston, MA, UNITED STATES  
PI US 2005153947 A1 20050714  
AI US 2004-947455 A1 20040920 (10)  
RLI Continuation of Ser. No. US 2004-777517, filed on 12 Feb 2004, PENDING  
Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003,  
PENDING  
PRAI US 2002-413040P 20020924 (60)  
US 2002-417261P 20021009 (60)  
US 2002-427424P 20021119 (60)  
US 2002-427526P 20021119 (60)  
US 2003-464753P 20030423 (60)  
DT Utility  
FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2921

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 50 OF 83 USPATFULL on STN

AN 2005:176868 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005152948 A1 20050714

AI US 2004-7838 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov

2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 96

ECL Exemplary Claim: 1-2174

DRWN 32 Drawing Page(s)

LN.CNT 12627

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 51 OF 83 USPATFULL on STN

AN 2005:176867 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005152947 A1 20050714

AI US 2004-6903 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 96

ECL Exemplary Claim: 1-1742

DRWN 32 Drawing Page(s)

LN.CNT 12637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 52 OF 83 USPATFULL on STN

AN 2005:176866 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005152946 A1 20050714

AI US 2004-6894 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 112

ECL Exemplary Claim: 1-1126

DRWN 32 Drawing Page(s)

LN.CNT 15056

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 53 OF 83 USPATFULL on STN

AN 2005:176865 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005152945 A1 20050714  
AI US 2004-6887 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 96  
ECL Exemplary Claim: 1-1310  
DRWN 32 Drawing Page(s)  
LN.CNT 12592

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 54 OF 83 USPATFULL on STN

AN 2005:176864 USPATFULL  
TI Soft tissue implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005152944 A1 20050714  
AI US 2004-6881 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 96  
ECL Exemplary Claim: 1-878  
DRWN 32 Drawing Page(s)  
LN.CNT 12628

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is

placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 55 OF 83 USPATFULL on STN  
AN 2005:176861 USPATFULL  
TI Soft tissue implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toliekis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005152941 A1 20050714  
AI US 2004-996353 A1 20041122 (10)  
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 132  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Page(s)  
LN.CNT 12685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 56 OF 83 USPATFULL on STN  
AN 2005:172408 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toliekis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 2005149157 A1 20050707  
AI US 2004-996355 A1 20041122 (10)  
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 111  
ECL Exemplary Claim: 1

DRWN 32 Drawing Page(s)

LN.CNT 14769

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 57 OF 83 USPATFULL on STN

AN 2005:164738 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005142162 A1 20050630

AI US 2004-1416 A1 20041201 (11)

RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-524023P 20031120 (60)

US 2003-523908P 20031120 (60)

US 2003-525226P 20031124 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 117

ECL Exemplary Claim: 1-4334

DRWN 32 Drawing Page(s)

LN.CNT 12679

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 58 OF 83 USPATFULL on STN

AN 2005:138510 USPATFULL

TI Methods and reagents for the treatment of immunoinflammatory disorders

IN Keith, Curtis, Boston, MA, UNITED STATES

Borisy, Alexis, Arlington, MA, UNITED STATES

Zimmermann, Grant R., Somerville, MA, UNITED STATES

Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES

Manivasakam, Palaniyandi, Brighton, MA, UNITED STATES

Hurst, Nicole, Boston, MA, UNITED STATES

Foley, Michael A., Chestnut Hill, MA, UNITED STATES

Slavonic, Michael S., Quincy, MA, UNITED STATES

Smith, Brendan, Boston, MA, UNITED STATES

Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

PI US 2005119160 A1 20050602

AI US 2004-966228 A1 20041015 (10)

PRAI US 2003-512415P 20031015 (60)

DT Utility

FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US  
CLMN Number of Claims: 53  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 59 OF 83 USPATFULL on STN

AN 2005:130740 USPATFULL

TI Therapeutic regimens for administering drug combinations

IN Padval, Mahesh, Waltham, MA, UNITED STATES

Elliott, Peter, Marlboro, MA, UNITED STATES

PI US 2005112199 A1 20050526

AI US 2004-947769 A1 20040923 (10)

RLI Continuation-in-part of Ser. No. US 2004-947455, filed on 20 Sep 2004, PENDING Continuation of Ser. No. US 2004-777517, filed on 12 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2004-944574, filed on 17 Sep 2004, PENDING Continuation-in-part of Ser. No. US 2004-777518, filed on 12 Feb 2004, PENDING

PRAI US 2003-520446P 20031113 (60)

US 2003-512415P 20031015 (60)

US 2004-557496P 20040330 (60)

DT Utility

FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US

CLMN Number of Claims: 55

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features dosing regimens for the administration of combination therapies, wherein one of the drugs of the combination is formulated for sustained release, or administered repeatedly, and compositions related thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 60 OF 83 USPATFULL on STN

AN 2005:125479 USPATFULL

TI Medical device with multiple coating layers

IN Wang, Xingwu, Wellsville, NY, UNITED STATES

Greenwald, Howard J., Rochester, NY, UNITED STATES

PI US 2005107870 A1 20050519

AI US 2004-923579 A1 20040820 (10)

RLI Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543,

filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US  
.2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser.  
No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609

DT Utility

FS APPLICATION

LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST  
ROCHESTER, NY, 14445-2408, US

CLMN Number of Claims: 62

ECL Exemplary Claim: 1

DRWN 54 Drawing Page(s)

LN.CNT 18628

AB An implantable medical device that contains two coating layers disposed  
above at least one of its surfaces. The first coating layer contains a  
biologically active material; and the second coating layer contains a  
polymeric material and nanomagnetic material disposed on the first  
coating layer; the second coating layer is substantially free of the  
biologically active material. The nanomagnetic material has a saturation  
magnetization of from about 2 to about 3000 electromagnetic units per  
cubic centimeter, and it contains nanomagnetic particles with an average  
particle size of less than about 100 nanometers; the average coherence  
length between adjacent nanomagnetic particles is less than 100  
nanometers.

L16 ANSWER 61 OF 83 USPATFULL on STN

AN 2005:92457 USPATFULL

TI Medical device with low magnetic susceptibility

IN Wang, Xingwu, Wellsville, NY, UNITED STATES

Greenwald, Howard J., Rochester, NY, UNITED STATES

Gunderman, Robert D., Honeyoye Falls, NY, UNITED STATES

PI US 2005079132 A1 20050414

AI US 2004-914691 A1 20040809 (10)

RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun  
2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on  
26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser.  
No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part  
of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004,  
PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec  
2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on  
22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420,  
filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US  
2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609

DT Utility

FS APPLICATION

LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST  
ROCHESTER, NY, 14445-2408, US

CLMN Number of Claims: 127

ECL Exemplary Claim: 1

DRWN 52 Drawing Page(s)

LN.CNT 17912

AB An assembly with a substrate, nanomagnetic material and magnetoresistive  
material. The nanomagnetic material has a saturation magnetization of  
from about 2 to about 3000 electromagnetic units per cubic centimeter;  
and it contains nanomagnetic particles with an average particle size of  
less than about 100 nanometers. The average coherence length between  
adjacent nanomagnetic particles is less than 100 nanometers.

L16 ANSWER 62 OF 83 USPATFULL on STN

AN 2005:30367 USPATFULL

TI Medical device with low magnetic susceptibility

IN Wang, Xingwu, Wellsville, NY, UNITED STATES

Greenwald, Howard Jay, Rochester, NY, UNITED STATES

PI US 2005025797 A1 20050203

AI US 2004-887521 A1 20040707 (10)

RLI Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609

DT Utility

FS APPLICATION

LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408

CLMN Number of Claims: 137

ECL Exemplary Claim: 1

DRWN 42 Drawing Page(s)

LN.CNT 17461

AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a magnetic susceptibility within the range of plus or minus 1+10.sup.-3 centimeter-gram-seconds

L16 ANSWER 63 OF 83 USPATFULL on STN

AN 2004:321764 USPATFULL

TI Therapeutic assembly

IN Wang, Xingwu, Wellsville, NY, UNITED STATES  
Greenwald, Howard J., Rochester, NY, UNITED STATES  
Lanzafame, John, Victor, NY, UNITED STATES  
Weiner, Michael L., Webster, NY, UNITED STATES  
Connelly, Patrick R., Rochester, NY, UNITED STATES

PI US 2004254419 A1 20041216

AI US 2004-867517 A1 20040614 (10)

RLI Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING

DT Utility

FS APPLICATION

LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408

CLMN Number of Claims: 175

ECL Exemplary Claim: CLM-1-177

DRWN 40 Drawing Page(s)

LN.CNT 16208

AB A therapeutic assembly that contains a therapeutic agent, a cytotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagnetic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius,

and a saturation magnetization of from about 2 to about 3,000  
electromagnetic units per cubic centimeter

L16 ANSWER 64 OF 83 USPATFULL on STN  
AN 2004:292760. USPATFULL  
TI Methods and reagents for the treatment of diseases and disorders  
associated with increased levels of proinflammatory cytokines  
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES  
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES  
Smith, Brendan, Boston, MA, UNITED STATES  
Fong, Jason, Philadelphia, PA, UNITED STATES  
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES  
Nichols, M. James, Boston, MA, UNITED STATES  
Keith, Curtis, Boston, MA, UNITED STATES  
Zimmermann, Grant R., Somerville, MA, UNITED STATES  
Brasher, Bradley B., Natick, MA, UNITED STATES  
Sachs, Noah, Boston, MA, UNITED STATES  
Chappell, Todd W., Boston, MA, UNITED STATES  
PI US 2004229849 A1 20041118  
AI US 2004-777517 A1 20040212 (10)  
RLI Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003,  
PENDING  
PRAI US 2002-413040P 20020924 (60)  
US 2002-417261P 20021009 (60)  
US 2002-427526P 20021119 (60)  
US 2002-427424P 20021119 (60)  
US 2003-464753P 20030423 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110  
CLMN Number of Claims: 86  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3245  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention features a method for treating a patient diagnosed with,  
or at risk of developing, an immunoinflammatory disorder by  
administering an SSRI or analog or metabolite thereof and, optionally, a  
corticosteroid or other compound to the patient. The invention also  
features a pharmaceutical composition containing an SSRI or  
analog or metabolite thereof and a corticosteroid or other compound for  
the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 65 OF 83 USPATFULL on STN  
AN 2004:286708 USPATFULL  
TI Combination therapy for the treatment of immunoinflammatory disorders  
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES  
Brasher, Bradley B., Natick, MA, UNITED STATES  
Chappell, Todd W., Boston, MA, UNITED STATES  
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES  
Sachs, Noah, Boston, MA, UNITED STATES  
Smith, Brendan, Boston, MA, UNITED STATES  
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES  
PI US 2004224876 A1 20041111  
AI US 2004-777518 A1 20040212 (10)  
PRAI US 2003-447366P 20030214 (60)  
US 2003-447412P 20030214 (60)  
US 2003-447415P 20030214 (60)  
US 2003-447553P 20030214 (60)  
US 2003-447648P 20030214 (60)  
US 2003-464753P 20030423 (60)

US 2003-503026P 20030915 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110  
CLMN Number of Claims: 61  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3770

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and an NsIDI enhancer (NsIDIE) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and NsIDIE or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 66 OF 83 USPATFULL on STN  
AN 2004:280852 USPATFULL  
TI Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines  
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES  
Manivasakam, Palaniyandi, W. Roxbury, MA, UNITED STATES  
Smith, Brendan, Boston, MA, UNITED STATES  
Fong, Jason, Philadelphia, PA, UNITED STATES  
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES  
Nichols, M. James, Boston, MA, UNITED STATES  
Keith, Curtis, Boston, MA, UNITED STATES  
Zimmermann, Grant R., Somerville, MA, UNITED STATES  
Brasher, Bradley B., Natick, MA, UNITED STATES  
Sachs, Noah, Boston, MA, UNITED STATES  
Chappell, Todd W., Boston, MA, UNITED STATES  
PI US 2004220153 A1 20041104  
AI US 2003-670488 A1 20030924 (10)  
PRAI US 2002-413040P 20020924 (60)  
US 2002-417261P 20021009 (60)  
US 2002-427526P 20021119 (60)  
US 2003-464753P 20030423 (60)

DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110  
CLMN Number of Claims: 77  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3183

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 67 OF 83 USPATFULL on STN  
AN 2004:240237 USPATFULL  
TI Cytomodulating peptides and methods for treating neurological disorders  
IN Iyer, Suhasini, San Ramon, CA, UNITED STATES

Buelow, Roland, Palo Alto, CA, UNITED STATES  
Lazarov, Mirella Emilova, Palo Alto, CA, UNITED STATES  
Fong, Timothy, Moraga, CA, UNITED STATES

PI US 2004186052 A1 20040923  
AI US 2003-693331 A1 20031024 (10)  
PRAI US 2002-421297P 20021024 (60)  
US 2002-431420P 20021205 (60)  
US 2003-470839P 20030515 (60)  
DT Utility  
FS APPLICATION  
LREP DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO  
CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 2528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for inhibiting neuronal cell death and the loss of neuronal contacts resulting from acute and chronic neurological disorders, including neurodegenerative and neuroinflammatory diseases. The subject compositions and methods utilize RDP-58 compositions capable of providing a direct neuroprotective effect on neuronal cells in conjunction with the inhibition of autoimmune and inflammatory processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 68 OF 83 USPATFULL on STN

AN 2003:264859 USPATFULL  
TI Formulations and methods for providing prolonged local anesthesia  
IN Chasin, Mark, Manalapan, NJ, UNITED STATES  
Goldenheim, Paul, Wilton, CT, UNITED STATES  
Sackler, Richard, Greenwich, CT, UNITED STATES  
Tigner, Joseph, New Milford, CT, UNITED STATES  
Burch, Ronald M., Wilton, CT, UNITED STATES  
PI US 2003185873 A1 20031002  
US 6921541 B2 20050726  
AI US 2002-237387 A1 20020909 (10)  
RLI Continuation of Ser. No. US 2000-522572, filed on 10 Mar 2000, PENDING  
Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999, GRANTED,  
Pat. No. US 6514516 Continuation of Ser. No. US 1997-793861, filed on 16  
Jun 1997, GRANTED, Pat. No. US 5942241 Continuation of Ser. No. WO  
1996-US10439, filed on 7 Jun 1996, PENDING  
PRAI US 1995-105P 19950609 (60)  
DT Utility  
FS APPLICATION  
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW  
YORK, NY, 10018  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1630

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 69 OF 83 USPATFULL on STN  
AN 2003:257302 USPATFULL  
TI Solid carriers for improved delivery of active ingredients in  
pharmaceutical compositions  
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES  
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
PI US 2003180352 A1 20030925  
AI US 2002-159601 A1 20020530 (10)  
RLI Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001,  
PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999,  
GRANTED, Pat. No. US 6248363  
DT Utility  
FS APPLICATION  
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 4625

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions  
for improved delivery of a wide variety of active ingredients contained  
therein or separately administered. In one embodiment, the solid  
pharmaceutical composition includes a solid carrier, the solid  
carrier including a substrate and an encapsulation coat on the  
substrate. The encapsulation coat can include different  
combinations of active ingredients, hydrophilic surfactant, lipophilic  
surfactants and triglycerides, and solubilizers. In another embodiment,  
the solid pharmaceutical composition includes a solid carrier,  
the solid carrier being formed of different combinations of active  
ingredients, hydrophilic surfactants, lipophilic surfactants and  
triglycerides, and solubilizers. The compositions of the  
present invention can be used for improved delivery of active  
ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 70 OF 83 USPATFULL on STN  
AN 2003:250571 USPATFULL  
TI Prolonged anesthesia in joints and body spaces  
IN Goldenhim, Paul, Wilton, CT, UNITED STATES  
Lacouture, Peter, Newton, CT, UNITED STATES  
Donigi-Gale, Donna, Richfield, CT, UNITED STATES  
Chasin, Mark, Manalapan, NJ, UNITED STATES  
Sackler, Richard, Greenwich, CT, UNITED STATES  
PI US 2003175357 A1 20030918  
AI US 2003-391242 A1 20030318 (10)  
RLI Continuation of Ser. No. US 2001-824465, filed on 2 Apr 2001, GRANTED,  
Pat. No. US 6534081 Continuation of Ser. No. US 1998-109324, filed on 2  
Jul 1998, GRANTED, Pat. No. US 6248345  
PRAI US 1997-51601P 19970702 (60)  
DT Utility  
FS APPLICATION  
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 15th Floor, 1140 Avenue of the  
Americas, New York, NY, 10036  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 2287

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained release local anesthetic formulations are  
administered intra articularly and/or into body spaces/cavities. The  
formulation is preferably a plurality of injectable microparticles

including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 71 OF 83 USPATFULL on STN  
AN 2003:219347 USPATFULL  
TI Local anesthetic, and method of use  
IN Chasin, Mark, Manalapan, NJ, UNITED STATES  
Buskirk, Glenn Van, Basking Ridge, NJ, UNITED STATES  
Maskiewicz, Richard, Ridgefield, CT, UNITED STATES  
Ketkar, Amol, Audobon, PA, UNITED STATES  
Burton, Kevin, Fishkill, NY, UNITED STATES  
Shameem, Mohammed, Nanuet, NY, UNITED STATES  
Landau, Craig, Norwalk, CT, UNITED STATES  
Coles, Celia, Easton, CT, UNITED STATES  
Swanton, Ruth, New Haven, CT, UNITED STATES  
Lacouture, Peter, Newton, CT, UNITED STATES  
PI US 2003152637 A1 20030814  
AI US 2002-57301 A1 20020125 (10)  
PRAI US 2001-264186P 20010125 (60)  
DT Utility  
FS APPLICATION  
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018  
CLMN Number of Claims: 93  
ECL Exemplary Claim: 1  
DRWN 57 Drawing Page(s)  
LN.CNT 12597

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to pharmaceutical formulations administered via parenteral methods, which provide a prolonged localized analgesic effect. More particularly, the present invention concerns a pharmaceutically acceptable biocompatible biodegradable carrier containing a local anesthetic and the parenteral administration of such carrier in a manner such that a localized analgesic effect is attained for a prolonged period of time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 72 OF 83 USPATFULL on STN  
AN 2003:53538 USPATFULL  
TI Formulations and methods for providing prolonged local anesthesia  
IN Goldenheim, Paul, Wilton, CT, United States  
Chasin, Mark, Manalapan, NJ, United States  
Sackler, Richard, Greenwich, CT, United States  
Burch, Ronald M., Wilton, CT, United States  
Tigner, Joseph, New Milford, CT, United States  
PA Euro-Celtique, S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6524607 B1 20030225  
AI US 2000-523361 20000310 (9)  
RLI Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999  
Continuation of Ser. No. US 793861, now patented, Pat. No. US 5942241, issued on 27 Dec 1996  
PRAI US 1995-105P 19950609 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Levy, Neil S.  
LREP Davidson, Davidson & Kappel, LLC  
CLMN Number of Claims: 1

ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1511  
AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

L16 ANSWER 73 OF 83 USPATFULL on STN  
AN 2003:47532 USPATFULL  
TI Formulations and methods for providing prolonged local anesthesia  
IN Chasin, Mark, Manalapan, NJ, United States  
Sackler, Richard, Greenwich, CT, United States  
Burch, Ronald M., Wilton, CT, United States  
Goldenheim, Paul, Wilton, CT, United States  
Tigner, Joseph, New Milford, CT, United States  
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6521259 B1 20030218  
AI US 2000-523360 20000310 (9)  
RLI Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999  
Continuation of Ser. No. US 793861, now patented, Pat. No. US 5942241  
PRAI US 1995-105P 19950609 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Levy, Neil S.  
LREP Davidson, Davidson & Kappel, LLC  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1759

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 74 OF 83 USPATFULL on STN  
AN 2003:33185 USPATFULL  
TI Formulations and methods for providing prolonged local anesthesia  
IN Chasin, Mark, Manalapan, NJ, United States  
Sackler, Richard, Greenwich, CT, United States  
Burch, Ronald M., Wilton, CT, United States  
Goldenheim, Paul, Wilton, CT, United States  
Tigner, Joseph, New Milford, CT, United States  
PA Euro-Celtique, S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6514516 B1 20030204  
AI US 1999-342964 19990629 (9)  
RLI Continuation of Ser. No. US 793861, now patented, Pat. No. US 5942241  
PRAI US 1995-105P 19950609 (60)

DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Levy, Neil S.  
LREP Davidson, Davidson & Kappel, LLC  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1802

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 75 OF 83 USPATFULL on STN

AN 2002:238665 USPATFULL  
TI Formulations and methods for providing prolonged local anesthesia  
IN Goldenheim, Paul, Wilton, CT, United States  
Donigi-Gale, Donna, Richfield, CT, United States  
Burton, Kevin, Fishkill, NY, United States  
Shameem, Mohammed, Elmsford, NY, United States  
Ketkar, Amol, Elmsford, NY, United States  
Chasin, Mark, Manalapan, NJ, United States  
Maskiewicz, Richard, Ridgefield, CT, United States  
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
PI US 6451335 B1 20020917  
AI US 1998-109323 19980702 (9)  
DT Utility  
FS GRANTED

EXNAM Primary Examiner: Azpuru, Carlos A.  
LREP Davidson, Davidson & Kappel, LLC  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 2273

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a non-toxic augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent. In preferred embodiments, the controlled release material is a low molecular weight, acid-terminated polymer. A further aspect of the invention is directed to such formulations which release the local anesthetic in two phases, the first a rapid "bolus" to initiate anesthesia and a second, slower release to maintain anesthesia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 76 OF 83 USPATFULL on STN

AN 2002:105713 USPATFULL  
TI Prolonged anesthesia in joints and body spaces  
IN Goldenheim, Paul, Wilton, CT, UNITED STATES

Lacouture, Peter, Newton, CT, UNITED STATES  
Donigi-Gale, Donna, Richfield, CT, UNITED STATES  
Chasin, Mark, Manalapan, NJ, UNITED STATES  
Sackler, Richard, Greenwich, CT, UNITED STATES

PI US 2002054915 A1 20020509  
US 6534081 B2 20030318  
AI US 2001-824465 A1 20010402 (9)  
RLI Continuation of Ser. No. US 1998-109324, filed on 2 Jul 1998, GRANTED,  
Pat. No. US 6248345  
PRAI US 1997-51601P 19970702 (60)  
DT Utility  
FS APPLICATION  
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 Seventh Avenue - 14th Floor, New  
York, NY, 10018  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 2285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 77 OF 83 USPATFULL on STN  
AN 2001:93113 USPATFULL  
TI Prolonged anesthesia in joints and body spaces  
IN Goldenheim, Paul, Wilton, CT, United States  
Lacouture, Peter, Newton, CT, United States  
Donigi-Gale, Donna, Richfield, CT, United States  
Chasin, Mark, Manalapan, NJ, United States  
Sackler, Richard, Greenwich, CT, United States  
PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)  
PI US 6248345 B1 20010619  
AI US 1998-109324 19980702 (9)  
PRAI US 1997-51601P 19970702 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Azpuru, Carlos A.  
LREP Davidson, Davidson, & Kappel, LLC.  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 2562

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 78 OF 83 USPATFULL on STN  
 AN 2001:78729 USPATFULL  
 TI High load formulations and methods for providing prolonged local anesthesia  
 IN Berde, Charles B., Brookline, MA, United States  
 Langer, Robert S., Newton, MA, United States  
 Curley, Joanne, San Jose, CA, United States  
 Castillo, Jenny, Philadelphia, PA, United States  
 PA Children's Medical Center Corp., Boston, MA, United States (U.S. corporation)  
 PI US 6238702 B1 20010529  
 AI US 1999-352511 19990712 (9)  
 RLI Continuation of Ser. No. US 1996-714782, filed on 16 Sep 1996, now patented, Pat. No. US 5922340 Continuation-in-part of Ser. No. US 1995-432402, filed on 1 May 1995, now patented, Pat. No. US 5700485 Continuation-in-part of Ser. No. US 1993-119958, filed on 10 Sep 1993, now patented, Pat. No. US 5618563 Continuation-in-part of Ser. No. US 1992-943287, filed on 10 Sep 1992, now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Spear, James M.; Assistant Examiner: Bennett, Rachel M  
 LREP Davidson, Davidson & Kappel, LLC  
 CLMN Number of Claims: 38  
 ECL Exemplary Claim: 1  
 DRWN 12 Drawing Figure(s); 6 Drawing Page(s)  
 LN.CNT 2024

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation for inducing sustained local anesthesia in a patient comprising a substrate comprising a high load of local anesthetic by weight and an effective amount of a biocompatible, controlled release material to obtain a. reversible nerve blockade or anesthesia effect when implanted or injected in a patient, and a non-toxic glucocorticosteroid agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the glucocorticosteroid agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 79 OF 83 USPATFULL on STN  
 AN 1999:99389 USPATFULL  
 TI Formulations and methods for providing prolonged local anesthesia  
 IN Chasin, Mark, Manalapan, NJ, United States  
 Sackler, Richard, Greenwich, CT, United States  
 Burch, Ronald M., Wilton, CT, United States  
 Goldenheim, Paul, Wilton, CT, United States  
 Tigner, Joseph, New Milford, CT, United States  
 PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)  
 PI US 5942241 19990824  
 WO 9641616 19961227  
 AI US 1997-793861 19970616 (8)  
 WO 1996-US10439 19960607  
 19970616 PCT 371 date  
 19970616 PCT 102(e) date  
 PRAI WO 1995-60000105 19950609  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Levy, Neil S.  
 LREP Davidson, Davidson & Kappel, LLC  
 CLMN Number of Claims: 41  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 1918

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation and methods for inducing sustained regional local

anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 80 OF 83 USPATFULL on STN  
AN 1999:78347 USPATFULL  
TI High load formulations and methods for providing prolonged local anesthesia  
IN Berde, Charles B., Brookline, MA, United States  
Langer, Robert S., Newton, MA, United States  
Curley, Joanne, San Jose, CA, United States  
Castillo, Jenny, Philadelphia, PA, United States  
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)  
PI US 5922340 19990713  
AI US 1996-714782 19960916 (8)  
RLI Continuation-in-part of Ser. No. US 1995-432402, filed on 5 May 1995, now patented, Pat. No. US 5700485 which is a continuation-in-part of Ser. No. US 1993-119958, filed on 10 Sep 1993, now patented, Pat. No. US 5618563 which is a continuation-in-part of Ser. No. US 1992-943287, filed on 10 Sep 1992, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kulkosky, Peter F.  
LREP Davidson, Davidson & Kappel, LLC  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 2066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation for inducing sustained local anesthesia in a patient comprising a substrate comprising a high load of local anesthetic by weight and an effective amount of a biocompatible, controlled release material to obtain a reversible nerve blockade or anesthesia effect when implanted or injected in a patient, and a non-toxic glucocorticosteroid agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the glucocorticosteroid agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 81 OF 83 USPAT2 on STN  
AN 2005:318834 USPAT2  
TI Compositions and methods for treating diverticular disease  
IN Hunter, William L, Vancouver, CANADA  
Toliekis, Philip M, Vancouver, CANADA  
Gravett, David M, Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Guan, Dechi, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 7241736 B2 20070710  
AI US 2005-129763 20050512 (11)  
RLI Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-518785P 20031110 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Monshipouri, Maryam; Assistant Examiner: Tsay, Marsha

LREP Seed IP Law Group PLLC

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 15 Drawing Figure(s); 15 Drawing Page(s)

LN.CNT 18529

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 82 OF 83 USPAT2 on STN

AN 2003:264859 USPAT2

TI Formulations and methods for providing prolonged local anesthesia

IN Chasin, Mark, Manalapan, NJ, UNITED STATES

Goldenheim, Paul, Wilton, CT, UNITED STATES

Sackler, Richard, Greenwich, CT, UNITED STATES

Tigner, Joseph, New Milford, CT, UNITED STATES

Burch, Ronald M, Wilton, CT, UNITED STATES

PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)

PI US 6921541 B2 20050726

AI US 2002-237387 20020909 (10)

RLI Continuation of Ser. No. US 2000-522572, filed on 10 Mar 2000, ABANDONED

Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999, Pat. No.

US 6514516 Continuation of Ser. No. US 793861, Pat. No. US 5942241 A 371

of International Ser. No. WO 1996-US10439, filed on 7 Jun 1996

PRAI US 1995-105P 19950609 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Levy, Neil S.

LREP Davidson, Davidson & Kappel, LLC

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 1858

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 83 OF 83 USPAT2 on STN

AN 2002:105713 USPAT2

TI Prolonged anesthesia in joints and body spaces

IN Goldenheim, Paul, Wilton, CT, United States

Donigi-Gale, Donna, Richfield, CT, United States

Sackler, Richard, Greenwich, CT, United States  
 Lacouture, Peter, Newton, CT, United States  
 Chasin, Mark, Manalapan, NJ, United States  
 PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)  
 PI US 6534081 B2 20030318  
 AI US 2001-824465 20010402 (9)  
 RLI Continuation of Ser. No. US 1998-109324, filed on 2 Jul 1998, now  
 patented, Pat. No. US 6248345  
 PRAI US 1997-51601P 19970702 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Azpuru, Carlos  
 LREP Davidson, Davidson & Kappel, LLC  
 CLMN Number of Claims: 31  
 ECL Exemplary Claim: 1  
 DRWN 2 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 2596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	420.33	420.96

FILE 'CAPLUS' ENTERED AT 11:52:04 ON 20 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2007 VOL 147 ISS 5

FILE LAST UPDATED: 19 Jul 2007 (20070719/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s Jin Tuo/AU

L17 36 JIN TUO/AU

=> s l17 and encapsul?

68019 ENCAPSUL?

L18 2 L17 AND ENCAPSUL?

=> dis 118 1-2 bib abs

L18 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2007:257414 CAPLUS  
DN 146:302401  
TI Polysaccharide microparticles containing biological agents  
IN Jin, Tuo; Wu, Fei; Yuan, Weien  
PA Peop. Rep. China  
SO PCT Int. Appl., 47pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007025441	A1	20070308	WO 2006-CN1777	20060720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-712548P P 20050829

AB This invention relates to method of preparing polysaccharide glassy microparticles which are less than 10µm in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous

emulsification (free of polyelectrolytes) and freezing-induced phase separation When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10µm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solns. and formulated to various forms of sustained release devices such as microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy. For example, fairly stable aqueous-aqueous emulsion was prepared by simply mixing dextran solution (containing 2

weight/weight% myoglobin) 10% with PEG solution 10% at 0-4°C. A small mol. sugar, trehalose 1% was added in the dextran solution for lyophilization and stored in refrigerator for 1 h. The sample was removed from the refrigerator and images were quickly taken before the dispersed phase fuses at elevated temperature The size of the dispersed dextran phase (the droplets) ranged between 3-7 µm in diameter This emulsion sample was then frozen at -20 0C, followed by lyophilization and dichloromethane-washing to remove the continuous PEG phase. The size reduction from 3-7 to 1-3 µm by lyophilization was due to dehydration.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:971951 CAPLUS  
 DN 140:19881  
 TI Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion  
 IN Jin, Tuo; Zhu, Hua; Zhu, Jiahao  
 PA Peop. Rep. China  
 SO PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101600	A2	20031211	WO 2003-CN431	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003059402	A1	20030327	US 2002-291327	20021108
	US 6998393	B2	20060214		
	CA 2487867	A1	20031211	CA 2003-2487867	20030603
	AU 2003245804	A1	20031219	AU 2003-245804	20030603
	EP 1572341	A2	20050914	EP 2003-737838	20030603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006504636	T	20060209	JP 2004-508943	20030603
	US 2006121121	A1	20060608	US 2006-517122	20060126
PRAI	US 2002-384971P	P	20020603		
	US 2002-418100P	P	20021011		
	US 2002-291327	A	20021108		
	US 2000-214037P	P	20000623		
	US 2001-886555	A	20010621		
	WO 2001-CN1033	W	20010622		
	WO 2003-CN431	W	20030603		

AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using a unique emulsion system (stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysaccharide glassy particles under a condition free of any chemical or phys. hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and crosslinking agents. Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the tech. challenges raised in sustained release delivery of proteins.

=> s Zhu Hua/AU  
 L19 198 ZHU HUA/AU

=> s l19 and encapsul?  
 68019 ENCAPSUL?

L20 1 L19 AND ENCAPSUL?

=> dis 120 bib abs

L20 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:971951 CAPLUS  
DN 140:19881  
TI Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion  
IN Jin, Tuo; Zhu, Hua; Zhu, Jiahao  
PA Peop. Rep. China  
SO PCT Int. Appl., 49 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101600	A2	20031211	WO 2003-CN431	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003059402	A1	20030327	US 2002-291327	20021108
	US 6998393	B2	20060214		
	CA 2487867	A1	20031211	CA 2003-2487867	20030603
	AU 2003245804	A1	20031219	AU 2003-245804	20030603
	EP 1572341	A2	20050914	EP 2003-737838	20030603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006504636	T	20060209	JP 2004-508943	20030603
	US 2006121121	A1	20060608	US 2006-517122	20060126
PRAI	US 2002-384971P	P	20020603		
	US 2002-418100P	P	20021011		
	US 2002-291327	A	20021108		
	US 2000-214037P	P	20000623		
	US 2001-886555	A	20010621		
	WO 2001-CN1033	W	20010622		
	WO 2003-CN431	W	20030603		

AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using a unique emulsion system (stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysaccharide glassy particles under a condition free of any chemical or phys. hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and crosslinking agents. Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the tech. challenges raised in sustained release delivery of proteins.

=> s Zhu Jiahao/AU

L21 4 ZHU JIAHAO/AU

=> dis 121 1-4 bib abs

- L21 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:304352 CAPLUS  
DN 145:59548  
TI Phylogenetics of the common pearl oysters in the genus *Pinctada*: evidence from nrDNA ITS sequence  
AU Yu, Dahui; Zhu, Jiahao  
CS South China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Guangzhou, Guangdong Province, 510300, Peop. Rep. China  
SO Shengwu Duoyangxing (2005), 13(4), 315-323  
CODEN: SHDUEM; ISSN: 1005-0094  
PB Kexue Chubanshe  
DT Journal  
LA Chinese  
AB Some species in the genus *Pinctada* are important resources for the pearl industry, but some of them are on the verge of extinction. The evolutionary relationship and identification some species in *Pinctada* were studied based on sequences of the internal transcribed spacers (ITS1 and ITS2) of nuclear ribosomal DNA (nrDNA). The length of ITS1 ranges 410-482 bp, with *P. margaritifera* and *P. maxima* being the longest, and *P. fucata*, *P. fucata martensii*, *P. imbricata*, and *P. nigra* the shortest. The length of ITS2 ranges 210-249 bp, with *P. albina* and *P. nigra* being the longest, and *P. margaritifera* and *P. maxima* the shortest. Homogeneity test on the pattern of nucleotide substitution indicates that the GC contents in *P. margaritifera* and *P. maxima* are significantly higher, and chromosomal rearrangements may have occurred in *P. chemnitzii*. This finding suggests that *P. margaritifera* and *P. maxima* are likely to be primitive species and *P. chemnitzii* appears to be a recent species. Phylogenetic anal. shows that the pearly oysters studied constitute 3 clades: clade I with *P. fucata*, *P. fucata martensii*, and *P. imbricata*; clade II with *P. albina*, *P. nigra*, *P. chemnitzii*, and *P. radiata*; and clade III with *P. margaritifera* and *P. maxima*. The insignificant genetic differentiation among the species in clade I indicate that they may be conspecific, with *P. imbricata* being the senior synonym. In clade II, the low genetic divergence between *P. albina* and *P. nigra* suggests that they may represent 2 subspecies. The ITS1 sequence of *P. radiata* in GenBank is almost identical to that of *P. chemnitzii* as determined in the present study, and thus we suspect that the specimen used for the *P. radiata* sequence in GenBank was misidentified. Clade III has a basal position, suggesting that species in this clade are more primitive than the others. This is congruent with the results revealed by the homogeneity test on the nucleotide substitution pattern.
- L21 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:21392 CAPLUS  
DN 145:206746  
TI Studies on genetic relationships between *Haliotis Diversicolor* and *H. Discus* using AFLP fingerprinting and DNA sequence analysis  
AU Wang, Zhiyong; Ke, Caihuan; Wang, Yilei; He, Jiaqi; Zhu, Jiahao  
CS Fisheries College, Jimei University, Xiamen, 361021, Peop. Rep. China  
SO Gaojishu Tongxun (2004), 14(12), 93-98  
CODEN: GTONE8; ISSN: 1002-0470  
PB Gaojishu Tongxun Zazhishe  
DT Journal  
LA Chinese  
AB *Haliotis diversicolor* and *Haliotis discus* are economically important abalone species in southern and northern China, resp. There are different opinions on systematic relationship between the two subspecies of *H. discus* and, particularly, of *H. diversicolor*. The aim of this study was to elucidate the genetic differences between the two species and their subspecies based on AFLP (Amplified Fragment Length Polymorphism) technol., sequence analyses of nuclear DNA [first internal transcribed spacer of rRNA (ITS-1) and 18S rRNA] and mitochondrial DNA [16S rRNA and

cytochrome oxidase I (COI) gene]. The results indicated that the genetic divergence between *H. diversicolor diversicolor* and *H. diversicolor supertexta* is small, probably only representing differences at the population level. Yet *H. discus discus* and *H. discus hannai* are genetically distinct based on AFLP fingerprinting pattern, thus justifying their subspecies status. AFLP technique was shown to be a simple, fast, highly reproducible, and thus a useful tool for evaluating genus identity and genetic diversity of abalone.

L21 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:101739 CAPLUS  
 DN 140:353814  
 TI A mini-review of studies on genetic basis of sex determination in fish  
 AU Tong, Jingou; Zhu, Jiahao; Guan, Haishan  
 CS Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei Province, 430072, Peop. Rep. China  
 SO Shuichan Xuebao (2003), 27(2), 169-176  
 CODEN: SHXUEK; ISSN: 1000-0615  
 PB Shuichan Xuebao Bianweihui  
 DT Journal; General Review  
 LA Chinese  
 AB A review. The authors discuss the progress in the past few decades in both cytogenetic and mol. genetic studies on sex determination in fish. The prospects, significance, and possible future directions of the studies on fish sex determination are also discussed.

L21 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:971951 CAPLUS  
 DN 140:19881  
 TI Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion  
 IN Jin, Tuo; Zhu, Hua; Zhu, Jiahao  
 PA Peop. Rep. China  
 SO PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101600	A2	20031211	WO 2003-CN431	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003059402	A1	20030327	US 2002-291327	20021108
	US 6998393	B2	20060214		
	CA 2487867	A1	20031211	CA 2003-2487867	20030603
	AU 2003245804	A1	20031219	AU 2003-245804	20030603
	EP 1572341	A2	20050914	EP 2003-737838	20030603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006504636	T	20060209	JP 2004-508943	20030603
	US 2006121121	A1	20060608	US 2006-517122	20060126
PRAI	US 2002-384971P	P	20020603		
	US 2002-418100P	P	20021011		
	US 2002-291327	A	20021108		
	US 2000-214037P	P	20000623		

US 2001-886555	A	20010621
WO 2001-CN1033	W	20010622
WO 2003-CN431	W	20030603

AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using a unique emulsion system (stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysaccharide glassy particles under a condition free of any chemical or phys. hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and crosslinking agents. Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the tech. challenges raised in sustained release delivery of proteins.

=> dis hist

(FILE 'HOME' ENTERED AT 11:18:20 ON 20 JUL 2007)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEK, WSCA, WTEXTILES, EMBASE, MEDLINE, BIOSIS' ENTERED AT 11:20:12 ON 20 JUL 2007

L1	7433789	S	COMPOSITION
L2	554816	S	L1 AND (POLYSACCHARIDE OR DEXTRAN OR STARCH OR CELLULOSE)
L3	8	S	L2 AND ECAPSUL?
L4	69931	S	L2 AND ENCAPSUL?
L5	55983	S	L4 AND (EPO OR ERYTHROPOIETIN OR CSF OR TPA OR INTERFERON O
L6	20251	S	L5 AND (PEG OR PEO OR PVP OR PVA)
L7	0	S	L6 AND (SOLID(A) OIL(A) WATER(A) EMULSION)
L8	20192	S	L6 AND (METHOD OR PROCESS)
L9	16	S	L8 AND (PARTICLES(W) DIAMETER)
L10	7614	S	L6 AND MICROSPHERE
L11	1444	S	L10 AND CHITOSAN
L12	1338	S	L11 AND DRUG
L13	405	S	L12 AND (PREDNISOLONE OR CORTISONE)
L14	236	S	L13 AND (CELLULOSE(A) ACETATE)
L15	181	S	L14 AND (SUSTAINED(A) RELEASE)
L16	83	S	L15 AND (AQUEOUS(W) SUSPENSION)

FILE 'CAPLUS' ENTERED AT 11:52:04 ON 20 JUL 2007

L17	36	S	JIN TUO/AU
L18	2	S	L17 AND ENCAPSUL?
L19	198	S	ZHU HUA/AU
L20	1	S	L19 AND ENCAPSUL?
L21	4	S	ZHU JIAHAO/AU